Conditions: Arthritis, Rheumatoid
Keywords: Phase 2 monotherapy in Japan
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 318
Healthy volunteers: no

Brief summary:
To evaluate the dose-response relationship of 5 dose of CP-690,550, compared to placebo for the treatment of signs and symptoms in patients with active RA who failed an adequate trial of therapy with at least 1 DMARD in a 12-week therapy.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None

Interventions: intervention 1: Placebo intervention 2: CP-690,550 intervention 3: CP-690,550 intervention 4: CP-690,550 intervention 5: CP-690,550 intervention 6: CP-690,550
Intervention descriptions: intervention 1: Placebo BID, 3 blinded tablets administered BID for 12 weeks intervention 2: 10mg BID, 3 blinded tablets administered BID for 12 weeks intervention 3: 15mg BID, 3 blinded tablets administered BID for 12 weeks intervention 4: 1mg BID, 3 blinded tablets administered BID for 12 weeks intervention 5: 3mg BID, 3 blinded tablets administered BID for 12 weeks intervention 6: 5mg BID, 3 blinded tablets administered BID for 12 weeks

Protocol document: